Brimonidine Tartrate + Placebos

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Graft Versus Host Disease

Conditions

Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease

Trial Timeline

Dec 23, 2018 → Apr 30, 2020

NCT ID

NCT03591874

About Brimonidine Tartrate + Placebos

Brimonidine Tartrate + Placebos is a phase 3 stage product being developed by Ocugen for Graft Versus Host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03591874. Target conditions include Graft Versus Host Disease, Ocular Surface Disease, oGVHD.

What happened to similar drugs?

20 of 20 similar drugs in Graft Versus Host Disease were approved

Approved (20) Terminated (1) Active (0)

✅Prograf + Methotrexate + CyclosporineAstellas PharmaApproved

✅tacrolimusAstellas PharmaApproved

✅azathioprine + sirolimusAstellas PharmaApproved

✅Aspirin + TicagrelorAstraZenecaApproved

✅SugammadexMerckApproved

✅RuxolitinibNovartisApproved

✅CyclosporineNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03591874	Phase 3	Terminated	Dec 23, 2018	Apr 30, 2020	Graft Versus Host Disease
NCT03785340	Phase 3	Completed	Dec 3, 2018	Feb 25, 2019	Dry Eye

Competing Products

20 competing products in Graft Versus Host Disease

See all competitors

Product	Company	Stage	Hype Score
Prograf + Methotrexate + Cyclosporine	Astellas Pharma	Approved	43
Alefacept	Astellas Pharma	Phase 2	27
tacrolimus	Astellas Pharma	Approved	43
Tacrolimus + Tacrolimus	Astellas Pharma	Pre-clinical	26
azathioprine + sirolimus	Astellas Pharma	Approved	43
Itolizumab + EQ001 Placebo	Biocon	Phase 3	32
EQ001 + EQ001 Placebo	Biocon	Phase 1/2	32
SHR0302	Jiangsu Hengrui Medicine	Phase 1	29
Acalabrutinib	AstraZeneca	Phase 2	39
Aspirin + Ticagrelor	AstraZeneca	Approved	43
Sugammadex	Merck	Approved	43
Efprezimod alfa + Methotrexate + Tacrolimus + Placebo	Merck	Phase 2	35
Ruxolitinib	Novartis	Approved	50
Imatinib Mesylate and Nilotinib	Novartis	Phase 2	35
Prednisone + Jakavi(ruxolitinib) + Prednisone	Novartis	Phase 2	42
PredEver	Novartis	Phase 2	35
Lifitegrast 5% Ophthalmic Solution + Placebo	Novartis	Phase 1	29
Cyclosporine	Novartis	Approved	39
Everolimus + Tacrolimus + Mycophenolic acid	Novartis	Approved	39
1 + 2	Novartis	Approved	43